NASDAQ:CAPRCapricor Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Capricor Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $5.39 +0.10 (+1.89 %) (As of 05/25/2020 04:00 PM ET) Add Compare Share Today's Range$5.20Now: $5.39▼$5.6550-Day Range$1.00MA: $4.15▼$8.5052-Week Range$0.88Now: $5.39▼$11.08Volume1.21 million shsAverage Volume15.26 million shsMarket Capitalization$76.86 millionP/E RatioN/ADividend YieldN/ABeta7.08 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders. Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingCapricor Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.50, Capricor Therapeutics has a potential upside of 94.8% from its current price of $5.39.Amount of Analyst CoverageCapricor Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.3 Community Rank Outperform VotesCapricor Therapeutics has received 320 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCapricor Therapeutics has received 371 “underperform” votes. (Add your “underperform” vote.)Community SentimentCapricor Therapeutics has received 53.69% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Capricor Therapeutics and other stocks. Vote “Outperform” if you believe CAPR will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CAPR will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCapricor Therapeutics does not currently pay a dividend.Dividend GrowthCapricor Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Capricor Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.60% of the stock of Capricor Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 3.50% of the stock of Capricor Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Capricor Therapeutics are expected to grow in the coming year, from ($1.46) to ($0.93) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Capricor Therapeutics is -3.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Capricor Therapeutics is -3.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCapricor Therapeutics has a P/B Ratio of 4.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.29 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CAPR Previous Symbol CUSIPN/A CIK1133869 Webwww.capricor.com Phone310-358-3200Debt Debt-to-Equity RatioN/A Current Ratio10.39 Quick Ratio10.39Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$1 million Price / Sales76.86 Cash FlowN/A Price / Cash FlowN/A Book Value$1.31 per share Price / Book4.11Profitability EPS (Most Recent Fiscal Year)($2.06) Net Income$-7,640,000.00 Net Margins-750.83% Return on Equity-128.89% Return on Assets-70.97%Miscellaneous EmployeesN/A Outstanding Shares14,260,000Market Cap$76.86 million Next Earnings Date8/4/2020 (Estimated) OptionableNot Optionable NASDAQ:CAPR Rates by TradingView Receive CAPR News and Ratings via Email Sign-up to receive the latest news and ratings for CAPR and its competitors with MarketBeat's FREE daily newsletter. Capricor Therapeutics (NASDAQ:CAPR) Frequently Asked Questions How has Capricor Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Capricor Therapeutics' stock was trading at $1.0050 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CAPR shares have increased by 436.3% and is now trading at $5.39. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Capricor Therapeutics? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Capricor Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Capricor Therapeutics. When is Capricor Therapeutics' next earnings date? Capricor Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Capricor Therapeutics. How were Capricor Therapeutics' earnings last quarter? Capricor Therapeutics Inc (NASDAQ:CAPR) announced its quarterly earnings data on Thursday, May, 14th. The biotechnology company reported ($0.30) EPS for the quarter, beating the Zacks' consensus estimate of ($0.33) by $0.03. The biotechnology company had revenue of $0.19 million for the quarter, compared to analyst estimates of $0.21 million. Capricor Therapeutics had a negative return on equity of 128.89% and a negative net margin of 750.83%. View Capricor Therapeutics' earnings history. What price target have analysts set for CAPR? 2 analysts have issued 12 month price objectives for Capricor Therapeutics' shares. Their forecasts range from $9.00 to $12.00. On average, they expect Capricor Therapeutics' share price to reach $10.50 in the next year. This suggests a possible upside of 94.8% from the stock's current price. View analysts' price targets for Capricor Therapeutics. Has Capricor Therapeutics been receiving favorable news coverage? News stories about CAPR stock have trended very negative this week, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Capricor Therapeutics earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news aboutCapricor Therapeutics. Who are some of Capricor Therapeutics' key competitors? Some companies that are related to Capricor Therapeutics include Rigel Pharmaceuticals (RIGL), Menlo Therapeutics (MNLO), Verastem (VSTM), Concert Pharmaceuticals (CNCE), Avid Bioservices (CDMO), Lannett (LCI), Neptune Wellness Solutions (NEPT), OrganiGram (OGI), Galera Therapeutics (GRTX), Chiasma (CHMA), Verrica Pharmaceuticals (VRCA), Mallinckrodt (MNK), Bicycle Therapeutics (BCYC), AMAG Pharmaceuticals (AMAG) and Abeona Therapeutics (ABEO). View all competitors. What other stocks do shareholders of Capricor Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Capricor Therapeutics investors own include Marinus Pharmaceuticals (MRNS), Chesapeake Energy (CHK), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Nabriva Therapeutics (NBRV), VBI Vaccines (VBIV), Agile Therapeutics (AGRX), Actinium Pharmaceuticals (ATNM), BioCryst Pharmaceuticals (BCRX) and BioMarin Pharmaceutical (BMRN). Who are Capricor Therapeutics' key executives? Capricor Therapeutics' management team includes the following people: Frank I. Litvack M.D., Independent Executive Chairman of the Board (Age 59)Linda Marban Ph.D., President, Chief Executive Officer, Director (Age 51)Anthony Bergmann, Chief Financial Officer, Principal Accounting Officer (Age 32)Karen G. Krasney J.D., Executive Vice President, General Counsel (Age 62)Thomas Lyle Copmann Ph.D., Vice President - Regulatory Affairs and Drug Development (Age 61)Houman Hemmati M.D., Ph.D., Vice President - Medical & Clinical Development, New TherapiesLuis Rodriguez-Borlado Ph.D., Vice President - Regenerative TherapiesRachel Smith Ph.D., Vice President - Research & Development (Age 36)Deborah Ascheim M.D., Chief Medical OfficerJoshua A. Kazam, Director (Age 40) What is Capricor Therapeutics' stock symbol? Capricor Therapeutics trades on the NASDAQ under the ticker symbol "CAPR." Who are Capricor Therapeutics' major shareholders? Capricor Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Jane Street Group LLC (0.19%). View institutional ownership trends for Capricor Therapeutics. Which major investors are buying Capricor Therapeutics stock? CAPR stock was bought by a variety of institutional investors in the last quarter, including Jane Street Group LLC. View insider buying and selling activity for Capricor Therapeutics. How do I buy shares of Capricor Therapeutics? Shares of CAPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Capricor Therapeutics' stock price today? One share of CAPR stock can currently be purchased for approximately $5.39. How big of a company is Capricor Therapeutics? Capricor Therapeutics has a market capitalization of $76.86 million and generates $1 million in revenue each year. The biotechnology company earns $-7,640,000.00 in net income (profit) each year or ($2.06) on an earnings per share basis. What is Capricor Therapeutics' official website? The official website for Capricor Therapeutics is www.capricor.com. How can I contact Capricor Therapeutics? Capricor Therapeutics' mailing address is 8840 WILSHIRE BLVD 2ND FLOOR, BEVERLY HILLS CA, 90211. The biotechnology company can be reached via phone at 310-358-3200 or via email at [email protected] This page was last updated on 5/26/2020 by MarketBeat.com Staff
